SCHEMBL22556715

SCHEMBL22556715

Nc1nc(CF)nc(SCc2ncc(-c3cc(Cl)ccc3Cl)o2)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.37
PDE4D Q08499 1/20 0.37
HSP90AA1 P07900 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 2/20 0.33
ALDH1A1 P00352 2/20 0.33
USP2 O75604 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.32
STAT1 P42224 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
PKM P14618 1/20 0.32
AGPAT2 O15120 1/20 0.32
MAPT P10636 2/20 0.31
POLB P06746 1/20 0.31
NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391010 1.00 HTR2B (0.37) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL29393818 0.90 HSP90AA1 (0.37) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL22556729 0.90 HSP90AA1 (0.37) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL22556717 0.88 HSP90AA1 (0.40) HSP90AA1SMN1; SMN2HPGDALDH1A1USP2
SCHEMBL29391048 0.88 HSP90AA1 (0.40) HSP90AA1SMN1; SMN2HPGDALDH1A1USP2
SCHEMBL22556783 0.85 HSP90AA1 (0.40) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL29391453 0.85 HSP90AA1 (0.40) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL22556755 0.85 HTR2B (0.36) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL29391458 0.85 HTR2B (0.36) HTR2BPDE4DHSP90AA1SMN1; SMN2HPGD
SCHEMBL22556706 0.84 ALDH1A1 (0.41) SMN1; SMN2HPGDALDH1A1USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 US disclosed
CN-116745289-A Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor 奥洛治疗有限公司 2023-09-12 CN disclosed
WO-2022083853-A1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR GBIOTECH S.À.R.L. (CH) 2022-04-28 WO disclosed
EP-3956323-A1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Gbiotech S.À.R.L. (CH) 2022-02-23 EP disclosed
WO-2020211956-A1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 GBIOTECH S.À.R.L. (CH) 2020-10-22 WO disclosed
WO-2020211956-A1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 GBIOTECH S.À.R.L. (CH) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 HTR2B 879/4885PDE4D 2899/4885HSP90AA1 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.